Seven Fleet Capital Management LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 2092021) · Explore on the interactive board
Seven Fleet Capital Management LP disclosed 96 US equity positions worth $605.9m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 17, 2026). Its largest position is CGON at 22.1% of the reported book, followed by TNGX, RVMD. The top ten holdings are 65.1% of the book, and the portfolio behaves like about 11 equal-weight positions. Versus the prior filing it opened 24 new positions, added to 43, reduced 22 and exited 25. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Seven Fleet Capital Management LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 24 new, 43 added, 22 reduced, 25 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | CGON CG ONCOLOGY INC | Healthcare | 22.1% | $134.0m | 1,886,236 | 2390% | added |
| 2 | TNGX TANGO THERAPEUTICS INC | Healthcare | 15.8% | $95.7m | 3,228,144 | 543% | added |
| 3 | RVMD REVOLUTION MEDICINES INC | Healthcare | 7.5% | $45.3m | 242,029 | 200% | added |
| 4 | PHVS PHARVARIS N V | Healthcare | 4.4% | $26.8m | 774,501 | 348% | added |
| 5 | LQDA LIQUIDIA CORPORATION | Healthcare | 3.4% | $20.5m | 256,603 | 37% | added |
| 6 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 3.1% | $18.5m | 365,386 | 123% | added |
| 7 | ABVX ABIVAX SA | Healthcare | 2.4% | $14.8m | 111,334 | 159% | added |
| 8 | AVTX AVALO THERAPEUTICS INC | Healthcare | 2.4% | $14.2m | 770,765 | 260% | added |
| 9 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 2.1% | $12.9m | 110,393 | – | new |
| 10 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 2.0% | $11.9m | 433,147 | 671% | added |
| 11 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 1.8% | $10.7m | 4,347,826 | 47% | added |
| 12 | CYTK CYTOKINETICS INC | Healthcare | 1.7% | $10.1m | 118,240 | 93% | added |
| 13 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 1.6% | $9.9m | 1,504,400 | 140% | added |
| 14 | MANE VERADERMICS INC | Healthcare | 1.6% | $9.8m | 80,000 | – | new |
| 15 | AVBP ARRIVENT BIOPHARMA INC | Healthcare | 1.4% | $8.6m | 246,606 | 391% | added |
| 16 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 1.3% | $7.9m | 117,067 | 491% | added |
| 17 | XNCR XENCOR INC | Healthcare | 1.3% | $7.8m | 368,305 | 360% | added |
| 18 | ROIV ROIVANT SCIENCES LTD | Healthcare | 1.3% | $7.8m | 220,126 | 72% | added |
| 19 | DMRA DAMORA THERAPEUTICS INC | Healthcare | 1.2% | $7.4m | 284,430 | 181% | added |
| 20 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.2% | $7.1m | 28,826 | 105% | added |
| 21 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 1.2% | $7.0m | 148,647 | 49% | added |
| 22 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 1.0% | $6.3m | 64,723 | 19% | added |
| 23 | COGT COGENT BIOSCIENCES INC | Healthcare | 0.9% | $5.7m | 147,510 | -1% | reduced |
| 24 | ERAS ERASCA INC | Healthcare | 0.9% | $5.6m | 308,007 | 38% | added |
| 25 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 0.9% | $5.6m | 45,400 | 1035% | added |
| 26 | NERV MINERVA NEUROSCIENCES INC | 0.9% | $5.6m | 1,001,373 | 303% | added | |
| 27 | EDIT EDITAS MEDICINE INC | Healthcare | 0.7% | $4.3m | 1,330,500 | – | new |
| 28 | CTMX CYTOMX THERAPEUTICS INC. | Healthcare | 0.7% | $4.1m | 1,085,398 | 192% | added |
| 29 | EPRX EUPRAXIA PHARMACEUTICALS INC | 0.7% | $4.0m | 610,785 | 41% | added | |
| 30 | STRO SUTRO BIOPHARMA INC | Healthcare | 0.6% | $3.8m | 159,118 | – | new |
| 31 | RLAY RELAY THERAPEUTICS INC | Healthcare | 0.6% | $3.3m | 178,222 | -31% | reduced |
| 32 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 0.5% | $3.2m | 86,664 | 196% | added |
| 33 | ASND ASCENDIS PHARMA A/S | Healthcare | 0.5% | $3.2m | 11,869 | – | new |
| 34 | SGMT SAGIMET BIOSCIENCES INC | Healthcare | 0.5% | $3.1m | 403,545 | – | new |
| 35 | ZLAB ZAI LAB LTD | Healthcare | 0.5% | $2.9m | 136,016 | 75% | added |
| 36 | SABS SAB BIOTHERAPEUTICS INC | 0.5% | $2.9m | 736,077 | 636% | added | |
| 37 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 0.4% | $2.7m | 4,973 | 47% | added |
| 38 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 0.4% | $2.5m | 7,540 | – | new |
| 39 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 0.4% | $2.4m | 348,265 | – | new |
| 40 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 0.3% | $2.1m | 56,900 | -73% | reduced |
| 41 | XENE XENON PHARMACEUTICALS INC | Healthcare | 0.3% | $2.1m | 33,300 | – | new |
| 42 | SVRA SAVARA INC | Healthcare | 0.3% | $1.9m | 309,103 | 5% | added |
| 43 | CCCC C4 THERAPEUTICS INC | Healthcare | 0.3% | $1.8m | 381,169 | 568% | added |
| 44 | PCVX VAXCYTE INC | Healthcare | 0.3% | $1.8m | 29,800 | -73% | reduced |
| 45 | CELC CELCUITY INC | Healthcare | 0.3% | $1.7m | 16,252 | 171% | added |
| 46 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 0.3% | $1.6m | 77,930 | – | new |
| 47 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 0.2% | $1.5m | 317,600 | 189% | added |
| 48 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.2% | $1.4m | 26,800 | 198% | added |
| 49 | LONA LEONABIO INC | 0.2% | $1.4m | 154,153 | -6% | reduced | |
| 50 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 0.2% | $1.4m | 37,865 | -56% | reduced |
What did Seven Fleet Capital Management LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| CG ONCOLOGY INC | 57.8% | $97.4m |
| TYRA TYRA BIOSCIENCES INC | 4.4% | $7.5m |
| TANGO THERAPEUTICS INC | 3.7% | $6.3m |
| AVALO THERAPEUTICS INC | 3.2% | $5.4m |
| MINERVA NEUROSCIENCES INC | 3.2% | $5.4m |
| PHARVARIS N V | 2.4% | $4.1m |
| SLNOEUR SOLENO THERAPEUTICS INC | 2.3% | $3.9m |
| ENLIVEN THERAPEUTICS INC | 2.2% | $3.7m |
| CYTOMX THERAPEUTICS INC. | 2.0% | $3.4m |
| CENTURY THERAPEUTICS INC | 1.9% | $3.2m |
| ASND ASCENDIS PHARMA A/S | 1.7% | $2.8m |
| 4XC1 KALVISTA PHARMACEUTICALS INC | 1.5% | $2.6m |
| COMPASS THERAPEUTICS INC | 1.3% | $2.2m |
| DIANTHUS THERAPEUTICS INC | 1.3% | $2.2m |
| EUPRAXIA PHARMACEUTICALS INC | 1.2% | $2.0m |
| MLYS MINERALYS THERAPEUTICS INC | 1.1% | $1.9m |
| SOLENO THERAPEUTICS INC | 1.1% | $1.8m |
| SAB BIOTHERAPEUTICS INC | 0.9% | $1.5m |
| VAXCYTE INC | 0.7% | $1.2m |
| REPL REPLIMUNE GROUP INC | 0.5% | $921.1k |
| MAZE MAZE THERAPEUTICS INC | 0.5% | $916.6k |
| CLYM CLIMB BIO INC | 0.5% | $895.0k |
| CMPS COMPASS PATHWAYS PLC | 0.5% | $873.9k |
| DNLI DENALI THERAPEUTICS INC | 0.4% | $677.5k |
| UTHR UNITED THERAPEUTICS RP DEL | 0.4% | $668.9k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 95.6% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Seven Fleet Capital Management LP's portfolio?
Across every quarter Seven Fleet Capital Management LP has filed, its median largest position is 26.4% of the book and its median top-ten weight is 58.2%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 42.0 completed holding spells, the median lasted 1.0 quarters; 96.0 positions are still open and their final length is unknown.